These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35022197)

  • 1. Determinants of Atrial Fibrillation Development among Patients undergoing Ibrutinib Therapy.
    Onitilo AA; Piwuna TO; Islam N; Furuya-Kanamori L; Kumar S; Doi SAR
    Clin Med Res; 2022 Mar; 20(1):16-22. PubMed ID: 35022197
    [No Abstract]   [Full Text] [Related]  

  • 2. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes.
    Archibald WJ; Rabe KG; Kabat BF; Herrmann J; Ding W; Kay NE; Kenderian SS; Muchtar E; Leis JF; Wang Y; Chanan-Khan AA; Schwager SM; Koehler AB; Fonder AL; Slager SL; Shanafelt TD; Call TG; Parikh SA
    Ann Hematol; 2021 Jan; 100(1):143-155. PubMed ID: 32488603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ibrutinib-Mediated Atrial Fibrillation Attributable to Inhibition of C-Terminal Src Kinase.
    Xiao L; Salem JE; Clauss S; Hanley A; Bapat A; Hulsmans M; Iwamoto Y; Wojtkiewicz G; Cetinbas M; Schloss MJ; Tedeschi J; Lebrun-Vignes B; Lundby A; Sadreyev RI; Moslehi J; Nahrendorf M; Ellinor PT; Milan DJ
    Circulation; 2020 Dec; 142(25):2443-2455. PubMed ID: 33092403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
    Mato AR; Clasen S; Pickens P; Gashonia L; Rhodes J; Svoboda J; Hughes M; Nabhan C; Ali N; Schuster S; Carver J
    Cancer Biol Ther; 2018 Jan; 19(1):1-2. PubMed ID: 29281559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
    Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
    Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
    Abdel-Qadir H; Sabrie N; Leong D; Pang A; Austin PC; Prica A; Nanthakumar K; Calvillo-Argüelles O; Lee DS; Thavendiranathan P
    J Clin Oncol; 2021 Nov; 39(31):3453-3462. PubMed ID: 34464154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for the development of atrial fibrillation on ibrutinib treatment.
    Lentz R; Feinglass J; Ma S; Akhter N
    Leuk Lymphoma; 2019 Jun; 60(6):1447-1453. PubMed ID: 30730240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.
    Sestier M; Hillis C; Fraser G; Leong D
    Curr Oncol Rep; 2021 Aug; 23(10):113. PubMed ID: 34342738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced cardiomyocyte reactive oxygen species signaling promotes ibrutinib-induced atrial fibrillation.
    Yang X; An N; Zhong C; Guan M; Jiang Y; Li X; Zhang H; Wang L; Ruan Y; Gao Y; Liu N; Shang H; Xing Y
    Redox Biol; 2020 Feb; 30():101432. PubMed ID: 31986467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilizing left atrial strain to identify patients at risk for atrial fibrillation on ibrutinib.
    Singh A; El Hangouche N; McGee K; Gong FF; Lentz R; Feinglass J; Akhter N
    Echocardiography; 2021 Jan; 38(1):81-88. PubMed ID: 33594858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
    Stühlinger MC; Weltermann A; Staber P; Heintel D; Nösslinger T; Steurer M
    Wien Klin Wochenschr; 2020 Feb; 132(3-4):97-109. PubMed ID: 31414181
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib.
    Avalon JC; Fuqua J; Miller T; Deskins S; Wakefield C; King A; Inderbitzin-Brooks S; Bianco C; Veltri L; Fang W; Craig M; Kanate A; Ross K; Malla M; Patel B
    Cardiooncology; 2021 Nov; 7(1):38. PubMed ID: 34798905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
    Ciuculete DC; Popescu RA; Dan GA
    Rom J Intern Med; 2021 Sep; 59(3):270-277. PubMed ID: 33913303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
    Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
    J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ibrutinib-related atrial fibrillation: A single center Australian experience.
    Ezad S; Khan AA; Cheema H; Ashraf A; Ngo DTM; Sverdlov AL; Collins NJ
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e187-e190. PubMed ID: 31250562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors and prognostic implications of incident heart failure following the first diagnosis of atrial fibrillation in patients with structurally normal hearts: the Belgrade Atrial Fibrillation Study.
    Potpara TS; Polovina MM; Licina MM; Marinkovic JM; Lip GY
    Eur J Heart Fail; 2013 Apr; 15(4):415-24. PubMed ID: 23302606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of ibrutinib-associated atrial fibrillation: 5-year follow-up of a prospective study.
    Mattiello V; Barone A; Giannarelli D; Noto A; Cecchi N; Rampi N; Cassin R; Reda G
    Hematol Oncol; 2023 Aug; 41(3):363-370. PubMed ID: 36762406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Right atrial structure and function in patients with hypertension and with chronic heart failure.
    Proplesch M; Merz AA; Claggett BL; Lewis EF; Dwyer KH; Crousillat DR; Lau ES; Silverman MB; Peck J; Rivero J; Cheng S; Platz E
    Echocardiography; 2018 Jul; 35(7):905-914. PubMed ID: 29600555
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ibrutinib-Associated Atrial Fibrillation.
    Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
    JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.